Project Grant R01CA293908
Award Date
6/21/24
Completion Date
5/31/29
Dollars Obligated
$691K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The federal Project Grant award, numbered HT94252410805, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award of $169,372.00 was granted to Brigham & Women's Hospital Inc., a nonprofit academic medical center in Boston, Massachusetts, to fund research on "ENGINEERING ANTAGOMIR NANODISCS TO REPROGRAM RCC-ASSOCIATED FIBROBLASTS". The award has a period of performance from July 1, 2024 to June 30, 2026....
This $437,906 project grant awarded on September 30, 2023 by the Defense Health Agency supports research by Brigham & Women's Hospital Inc. to develop enhanced immunotherapy and targeted therapy approaches for non-small cell lung cancer. The project is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports a wide range of biomedical research efforts targeting improved healthcare for Service Members, Veterans, and the public....
The federal Project Grant award of $1,428,720.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by Brigham & Women's Hospital Inc. to investigate menin/KMT2A protein degradation for the treatment of myeloid neoplasms. The award runs from August 1, 2025 to July 31, 2029. Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts, will conduct this...
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...
The federal Project Grant award, titled "TARGETING TP53 TO ENHANCE IMMUNOTHERAPY," was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $154,632 grant was awarded to Brigham & Women's Hospital Inc., a non-profit academic medical center in Boston, MA, on June 1, 2024. The funding supports advanced biomedical research focused on investigating innovative approaches to enhance immunotherapy through targeting the TP53...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...